Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy


Por: Schcolnik-Cabrera, Alejandro, Chavez-Blanco, Alma, Dominguez-Gomez, Guadalupe, Taja-Chayeb, Lucia, Morales-Barcenas, Rocio, Trejo-Becerril, Catalina, Perez-Cardenas, Enrique, Gonzalez-Fierro, Aurora, Duenas-Gonzalez, Alfonso

Publicada: 1 ene 2018
Resumen:
Introduction: Cancer cells have increased glycolysis and glutaminolysis. Their third feature is increased de novo lipogenesis. As such, fatty acid (FA) synthesis enzymes are over-expressed in cancer and their depletion causes antitumor effects. As fatty acid synthase (FASN) plays a pivotal role in this process, it is an attractive target for cancer therapy. Areas covered: This is a review of the lipogenic phenotype of cancer and how this phenomenon can be exploited for cancer therapy using inhibitors of FASN, with particular emphasis on orlistat as a repurposing drug. Expert opinion: Disease stabilization only has been observed with a highly selective FASN inhibitor used as a single agent in clinical trials. It is too early to say whether the absence of tumor responses other than stabilization results because even full inhibition of FASN is not enough to elicit antitumor responses. The FASN inhibitor orlistat is a ‘dirty’ drug with target-off actions upon at least seven targets with a proven role in tumor biology. The development of orlistat formulations suited for its intravenous administration is a step ahead to shed light on the concept that drug promiscuity can or not be a virtue. © 2018 Informa UK Limited, trading as Taylor & Francis Group.

Filiaciones:
Schcolnik-Cabrera, Alejandro:
 Inst Nacl Cancerol, Div Basic Res, Mexico City, DF, Mexico

Chavez-Blanco, Alma:
 Inst Nacl Cancerol, Div Basic Res, Mexico City, DF, Mexico

Dominguez-Gomez, Guadalupe:
 Inst Nacl Cancerol, Div Basic Res, Mexico City, DF, Mexico

Taja-Chayeb, Lucia:
 Inst Nacl Cancerol, Div Basic Res, Mexico City, DF, Mexico

Morales-Barcenas, Rocio:
 Inst Nacl Cancerol, Div Basic Res, Mexico City, DF, Mexico

Trejo-Becerril, Catalina:
 Inst Nacl Cancerol, Div Basic Res, Mexico City, DF, Mexico

Perez-Cardenas, Enrique:
 Inst Nacl Cancerol, Div Basic Res, Mexico City, DF, Mexico

Gonzalez-Fierro, Aurora:
 Inst Nacl Cancerol, Div Basic Res, Mexico City, DF, Mexico

Duenas-Gonzalez, Alfonso:
 Univ Nacl Autonoma Mexico, Inst Nacl Cancerol, Inst Invest Biomed, Unit Biomed Res Canc, Mexico City, DF, Mexico
ISSN: 13543784
Editorial
INFORMA HEALTHCARE, TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND, Reino Unido
Tipo de documento: Review
Volumen: 27 Número: 5
Páginas: 475-489
WOS Id: 000432689500005
ID de PubMed: 29723075

MÉTRICAS